Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.9894
- Book/Share 38.2151
- PB 9.8439
- Debt/Equity 0.5957
- CurrentRatio 0.7761
- ROIC 0.3599
- MktCap 1672167340050.0557
- FreeCF/Share 14.1116
- PFCF 26.6536
- PE 16.1163
- Debt/Assets 0.1976
- DivYield 0.0209
- ROE 0.6695
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVO | Argus | Buy | Hold | -- | -- | Dec. 8, 2025 |
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
News
Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs
Published: January 12, 2026 by: Reuters
Sentiment: Negative
Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of blockbuster GLP-1 drugs, underscoring how cheaper, unapproved alternatives have captured a significant share of demand for obesity treatments.
Read More
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight-loss pill
Published: January 09, 2026 by: CNBC
Sentiment: Positive
Amazon said it now offers Novo Nordisk's Wegovy weight-loss pill through its digital pharmacy service. Novo Nordisk began rolling out its first-ever GLP-1 pill in the U.S. earlier this week.
Read More
Amazon Pharmacy offers Novo Nordisk's Wegovy pill
Published: January 09, 2026 by: Reuters
Sentiment: Positive
Amazon Pharmacy said on Friday it now offers Novo Nordisk's Wegovy pill through insurance plans as well as through a cash-pay option.
Read More
Novo Nordisk: My Top Pick For 2026
Published: January 08, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk: My Top Pick For 2026
Read More
Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.
Read More
Novo Nordisk: NVO Stock To $100?
Published: January 06, 2026 by: Forbes
Sentiment: Positive
Novo Nordisk's (NYSE: NVO) Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x story moving forward, provided it effectively leverages this first‑mover oral advantage into sustainable volume, pricing authority, and pipeline reliability against Eli Lilly. The stock has increased by approximately 17% in the last month, yet it still remains significantly below its 52‑week peak near 94, suggesting potential for a significant rerating if multiple growth drivers are activated simultaneously.
Read More
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
Published: January 05, 2026 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S (NYSE: NVO) on Monday said the Wegovy pill is now available, which was approved in December 2025.
Read More
Novo Nordisk launches first oral GLP-1 weight loss pill in the US
Published: January 05, 2026 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) has made its Wegovy pill, the first oral GLP-1 treatment for weight loss, broadly available to patients in the United States. The launch marks a new development in obesity treatment, offering a once-daily pill alternative to weekly injections that have dominated the market.
Read More
China Market Unsettled, But Novo Nordisk's Oral Wegovy May Keep Revenue On Track
Published: January 05, 2026 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S launches oral Wegovy in the U.S. at aggressive introductory pricing, aiming to secure early market share and first-mover advantage. NVO faces imminent semaglutide patent expiry in China, triggering a wave of local competition and likely sharp margin compression in 2026. Novo's China revenue, about 6.5% of total, is expected to decline, but U.S. oral GLP-1 ramp should offset regional headwinds.
Read More
Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.
Published: January 05, 2026 by: Market Watch
Sentiment: Positive
Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.
Read More
Exclusive: Novo Nordisk's US public affairs head leaves company
Published: January 05, 2026 by: Reuters
Sentiment: Negative
Danish obesity drugmaker Novo Nordisk's head of public affairs in the U.S. has left the company, according to an internal memo seen by Reuters, at a time when the firm is battling to revive its fortunes in its top market.
Read More
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.
Read More
Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.
Read More
Novo Nordisk enters 2026 on the defense as it faces a ‘must-win' battle in the U.S. market
Published: January 01, 2026 by: CNBC
Sentiment: Negative
2026 is set to be a year of transition for the Danish drugmaker, as it faces headwinds including lower pricing on multiple fronts and patent expiries in Brazil, Canada, and China. It follows a difficult year for Novo, marked by volatility and a declining share price.
Read More
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Published: December 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
Published: December 29, 2025 by: Zacks Investment Research
Sentiment: Positive
FDA approval of NVO's oral Wegovy could reshape obesity care and lift healthcare ETFs, offering investors diversified exposure to the GLP-1 boom.
Read More
This Beaten-Down Stock Just Jumped By 8%. Time to Buy?
Published: December 29, 2025 by: The Motley Fool
Sentiment: Positive
Pharmaceutical giant Novo Nordisk just earned approval for an oral version of Wegovy. This could help improve its position in the increasingly competitive weight loss market.
Read More
Oral Wegovy Approval Is The Critical 2026 Lifeline Novo Nordisk Needs
Published: December 26, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S secured FDA approval for oral Wegovy, marking a pivotal expansion in the obesity treatment market. Oral GLP-1 therapies promise greater accessibility and a potentially larger addressable market compared to injectables. NVO's obesity segment, though less reimbursed than diabetes, is growing rapidly at 41% year over year versus 10% for diabetes.
Read More
Bear of the Day: Novo Nordisk (NVO)
Published: December 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk ( NVO ) is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human insulins. Based in Bagsværd, Denmark the company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.
Read More
Focus: Lilly, Novo lock horns in India's obesity drug race
Published: December 23, 2025 by: Reuters
Sentiment: Neutral
Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.
Read More
Final Trade: NVO, FCX, BA, CLF
Published: December 23, 2025 by: CNBC Television
Sentiment: Neutral
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Read More
Launch of Wegovy pill is core to Novo Nordisk's growth, says Guggenheim's Seamus Fernandez
Published: December 23, 2025 by: CNBC Television
Sentiment: Positive
Guggenheim's Seamus Fernandez joins 'Fast Money' to talk Novo Nordisk getting Wegovy pill approved.
Read More
Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly's Looming Pill?
Published: December 23, 2025 by: 24/7 Wall Street
Sentiment: Positive
Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk ‘s ( NYSE:NVO ) Wegovy weight-loss pill, the first of its kind.
Read More
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.
Read More
Could Novo Nordisk's New Weight-Loss Pill Be Just What Its Stock Needs?
Published: December 23, 2025 by: Investopedia
Sentiment: Positive
Could a new weight-loss pill be just what Novo Nordisk (NVO) needs to revive its stock?
Read More
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
Read More
Novo Nordisk Stock Soars on FDA-Cleared GLP-1 Pill
Published: December 23, 2025 by: Schaeffers Research
Sentiment: Positive
Novo Nordisk A/S (NYSE:NVO) stock is up 8.8% to trade at $52.37 at last check, after the biopharmaceutical giant received approval from the U.S. Food & Drug Administration (FDA) for the first ever GLP-1 pill.
Read More
Novo CEO Says Wegovy Pill Is Safe and Will Be Widely Available
Published: December 23, 2025 by: Bloomberg Markets and Finance
Sentiment: Positive
Novo Nordisk President and CEO Mike Doustdar says Christmas has come early with US approval of its Wegovy weight loss pill. He says the company is going "all-in" and they are super excited to be the first to market.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406